SUVmax | Blood flow (mL/min/g) | |||||||
Variable | Parameter | n | Median | Interquartile range | P | Median | Interquartile range | P |
Menopausal | No | 22 (55%) | 6.7 | 5.2–9.9 | 0.48 | 0.31 | 0.23–0.38 | 0.72 |
Yes | 18 (45%) | 6.8 | 5.0–14.5 | 0.32 | 0.20–0.43 | |||
Tumor size | <5 cm | 24 (60%) | 6.8 | 5.3–10.2 | 0.50 | 0.33 | 0.21–0.38 | 0.29 |
≥5 cm | 16 (40%) | 7.9 | 5.0–13.3 | 0.31 | 0.22–0.47 | |||
Lymph node involvement | No | 13 (32%) | 5.4 | 3.9–13.0 | 0.54 | 0.28 | 0.20–0.39 | 0.40 |
Yes | 27 (68%) | 7.9 | 5.5–11.7 | 0.33 | 0.23–0.42 | |||
Histologic grade | 1/2 | 26 (65%) | 5.6 | 4.0–8.1 | <0.001 | 0.27 | 0.20–0.37 | 0.030 |
3 | 14 (35%) | 13.3 | 8.5–16.3 | 0.39 | 0.32–0.46 | |||
ER | − | 14 (35%) | 10.3 | 6.8–12.9 | 0.08 | 0.29 | 0.20–0.43 | 0.86 |
+ | 26 (65%) | 6.1 | 4.6–8.9 | 0.32 | 0.23–0.40 | |||
PR | − | 19 (48%) | 9.2 | 6.5–12.7 | 0.021 | 0.36 | 0.25–0.42 | 0.18 |
+ | 21 (52%) | 5.5 | 3.1–9.3 | 0.28 | 0.20–0.38 | |||
HER2 | − | 25 (63%) | 9.3 | 4.5–13.0 | 0.60 | 0.28 | 0.20–0.45 | 0.64 |
+ | 15 (37%) | 6.5 | 5.5–8.1 | 0.33 | 0.27–0.38 | |||
TN | Non-TN | 30 (75%) | 6.4 | 5.1–9.0 | 0.042 | 0.32 | 0.23–0.39 | 0.82 |
TN | 10 (25%) | 11.9 | 10.2–14.2 | 0.23 | 0.18–0.45 | |||
Lymphovascular invasion | No | 6 (15%) | 6.9 | 5.3–11.2 | 0.65 | 0.32 | 0.21–0.38 | 0.91 |
Yes | 34 (85%) | 5.4 | 3.6–12.1 | 0.28 | 0.22–0.41 | |||
Ki67 score | ≤median | 23 (58%) | 5.7 | 3.5–7.0 | <0.001 | 0.28 | 0.19–0.37 | 0.09 |
>median | 17 (42%) | 12.1 | 7.9–14.6 | 0.38 | 0.25–0.45 | |||
CD34 score | ≤median | 20 (50%) | 7.7 | 4.6–12.6 | 0.57 | 0.24 | 0.17–0.38 | 0.027 |
>median | 20 (50%) | 6.6 | 5.4–10.7 | 0.36 | 0.26–0.46 | |||
CD105 score | ≤median | 20 (50%) | 6.1 | 3.7–12.6 | 0.31 | 0.23 | 0.17–0.32 | 0.002 |
>median | 20 (50%) | 7.5 | 6.4–11.9 | 0.37 | 0.32–0.44 |